Rowland Charles A Jr 4
4 · Viking Therapeutics, Inc. · Filed Oct 28, 2025
Insider Transaction Report
Form 4
Rowland Charles A Jr
Director
Transactions
- Award
Common Stock, par value $0.00001 per share
2025-10-27$4.88/sh+22,000$107,360→ 90,000 total - Award
Common Stock, par value $0.00001 per share
2025-10-27$4.48/sh+16,000$71,680→ 46,000 total - Award
Common Stock, par value $0.00001 per share
2025-10-27$5.80/sh+22,000$127,600→ 68,000 total - Sale
Common Stock, par value $0.00001 per share
2025-10-27$35.57/sh−60,000$2,134,278→ 30,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-27−16,000→ 0 totalExercise: $4.48From: 2019-01-02Exp: 2028-01-02→ Common Stock (16,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-27−22,000→ 0 totalExercise: $4.88From: 2023-01-03Exp: 2032-01-03→ Common Stock (22,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-27−22,000→ 0 totalExercise: $5.80From: 2022-01-04Exp: 2031-01-04→ Common Stock (22,000 underlying)
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.